Quantcast
Last updated on April 21, 2014 at 1:20 EDT

CareFusion Reports Third Quarter Fiscal 2012 Results

May 3, 2012

SAN DIEGO, May 3, 2012 /PRNewswire/ — CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the three and nine months ended March 31, 2012.

“Our team executed well in the third quarter, particularly in the Medical Systems segment where Dispensing, Infusion and Respiratory Technologies all reported double-digit revenue growth,” said Kieran Gallahue, chairman and CEO. “Our Procedural Solutions segment performed as we expected, with strength in the Infection Prevention business and sales of ChloraPrep growing in line with our expectations.

“We continued to make good progress during the quarter on strategies to optimize our portfolio, simplify the complexity of our infrastructure and reduce expenses to fund growth initiatives. This work showed multiple benefits during the quarter as we closed on the Phacts acquisition, announced plans to divest the Nicolet business and increased R&D investments that we funded by lowering our organic SG&A expenses.”

Last month, the company announced it had reached an agreement to divest its Nicolet neurodiagnostic and monitoring products business to Natus Medical Incorporated for $58 million. The Nicolet business, which had been included in the Procedural Solutions segment, has been classified as discontinued operations in the accompanying financial tables. Reported results from continuing operations and comparisons to prior periods exclude the historical results of the Nicolet business.

Third Quarter Results

The company reported revenue for the third quarter of fiscal 2012 of $919 million, compared to $842 million in the third quarter of fiscal 2012, an increase of 9 percent on a reported and constant currency basis.

Operating income was $161 million, an increase of 10 percent compared to $146 million in the prior year period. Excluding nonrecurring items, adjusted operating income rose 12 percent to $173 million, compared to $155 million in the prior year.

Operating expenses totaled $298 million. Excluding nonrecurring items, adjusted operating expenses were $286 million, an increase of 1 percent over the prior year period, primarily driven by operating expenses from Rowa Technologies, which the company acquired in August 2011. In addition, the company increased investments in research and development by 25 percent during the quarter and benefited from ongoing cost-savings initiatives in administrative support functions.

The company reported income from continuing operations of $103 million, or $0.45 per diluted share. Adjusted income from continuing operations increased 19 percent from the prior year period to $112 million, or $0.49 per diluted share. The adjusted effective tax rate was 26.0 percent.

Medical Systems

Third quarter revenue for the Medical Systems segment increased 19 percent from the prior year period on a reported and constant currency basis to $591 million, driven by double-digit sales increases in each business. The segment growth was led by continued strong installations in the Dispensing Technologies and Infusion Systems businesses, as well as growth in Respiratory Technologies resulting from increased sales to acute care hospitals and a significant government contract that will continue through March of 2013.

Segment profit for the quarter increased 29 percent from the prior year period to $125 million, and adjusted segment profit increased 21 percent to $132 million.

Procedural Solutions

Third quarter revenue for the Procedural Solutions segment decreased 5 percent from the prior year period on a reported and constant currency basis to $328 million. The decrease was driven, in part, by the loss of sales from divesting the company’s OnSite Services business in March 2011. Net of the OnSite Services business divestiture, segment revenues decreased 2 percent from the prior year period.

Segment profit increased 6 percent from the prior year period to $36 million, and adjusted segment profit decreased 11 percent to $41 million.

Nine Month Results

For the first nine months of fiscal 2012, revenue increased 6 percent from the prior year period to $2.63 billion. Operating income increased 19 percent to $414 million from $348 million in the prior year period. Income from continuing operations was $266 million, or $1.17 per diluted share. Adjusted income from continuing operations increased 13 percent from the prior year period to $288 million, or $1.27 per diluted share.

Operating expenses in the first nine months totaled $910 million, or $880 million on an adjusted basis. R&D expenses increased 9 percent from the prior year period, reflecting the company’s continued investments in product development and innovation.

Within the Medical Systems segment, revenue increased 12 percent from the prior year period to $1.67 billion. Segment profit increased 28 percent to $334 million, an increase of 14 percent to $352 million on an adjusted basis.

Revenue for the Procedural Solutions segment decreased 4 percent from the prior year period to $961 million. Segment profit increased 10 percent to $80 million, a decrease of 19 percent to $92 million on an adjusted basis.

Recent Highlights

Additional third quarter and recent highlights included:

  • Initiating a two-year, $500 million share repurchase program and investing $50 million to repurchase 2 million shares during the quarter. The company purchased an additional 1.9 million shares for $50 million in April.
  • Receiving a three-year, single-source award for ChloraPrep® applicators from Novation, a health care supply contracting company, in its chlorhexidine gluconate preoperative skin prep category.
  • Strengthening the company’s end-to-end medication management offering by completing the acquisition of Phacts, a technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations.
  • Launching the Alaris® Connectivity Services – Infusion Parameter Pre-Population application, helping hospitals improve infusion safety and clinician workflow through wireless interoperability.
  • Announcing the Snowden-Pencer® laparoscopic take-apart instrument line, a portfolio of surgical instruments that can be easily disassembled to aid in cleaning and sterilization.

Fiscal 2012 Outlook

CareFusion raised full-year consolidated revenue growth guidance from a 3 to 5 percent range to a new range of 4 to 5 percent growth on a constant currency basis. This growth rate is compared to fiscal 2011 revenue of $3.43 billion, which reflects fiscal 2011 revenue net of the Nicolet divestiture. The company also narrowed its full-year guidance range for adjusted diluted EPS from continuing operations of $1.75 to $1.85 to a new range of $1.75 to $1.80. The change reflects a $0.02 reduction for the planned divestiture of CareFusion’s Nicolet business and narrowing based on the company’s expectations entering the fourth quarter.

The guidance is based on an assumed diluted weighted average outstanding share count of approximately 226 million, which includes the impact of expected share repurchases during fiscal 2012.

Conference Call

CareFusion will host a webcast and conference call today at 2 p.m. PDT (5 p.m. EDT) to discuss the results for the third quarter fiscal 2012.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (888) 396-2369 within the U.S. or (617) 847-8710 from outside the U.S., and use the access code 88204211. A replay of the conference call will be available from 5 p.m. PDT (8 p.m. EDT) on May 3 through 8:59 p.m. PDT (11:59 p.m. EDT) on May 10 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 internationally and using the access code 14284150.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife(TM) and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, Nicolet(TM) neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release and the information contained herein present non-GAAP financial measures that exclude certain amounts, as follows: “adjusted SG&A expenses,” which exclude nonrecurring items primarily related to the spinoff; “adjusted operating expenses,” “adjusted operating income” and “adjusted segment profit,” which exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges; and “adjusted income from continuing operations,” “adjusted diluted earnings per share from continuing operations” and “adjusted effective tax rate,” which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items. The most directly comparable GAAP financial measures for these non-GAAP financial measures are SG&A expenses, operating expenses, operating income, segment profit, income from continuing operations, diluted earnings per share from continuing operations and effective tax rate. The company has included below unaudited adjusted financial information for the quarters and nine months ended March 31, 2012 and 2011, which includes a reconciliation of GAAP to non-GAAP financial measures.

The company’s management uses these non-GAAP financial measures to evaluate the company’s performance and provides them to investors as a supplement to the company’s reported results, as they believe this information provides additional insight into the company’s operating performance by disregarding certain non-recurring items. These non-GAAP financial measures should not be considered in isolation, as a substitute for, or as superior to, financial measures calculated in accordance with GAAP, and the company’s financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. While the types of items and charges excluded from the company’s non-GAAP financial measures may occur in the future, the company’s management believes that they are not reflective of the day-to-day offering of its products and services and relate more to strategic, multi-year corporate actions, without predictable trends, or discrete and unusual or infrequent transactions that are not indicative of future operations or business trends.

Cautions Concerning Forward-looking Statements

The CareFusion news release and the information contained herein present forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion’s Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management’s views as of May 3, 2012. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                                                                                            CAREFUSION CORPORATION
                                                                                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                                                                                 (UNAUDITED)

                                                                           Quarter Ended                     Nine Months Ended
                                                                             March 31,                           March 31,
                                                                             ---------                           ---------
    (in millions, except per share amounts)                                              2012                                2011                                2012                                2011
    --------------------------------------                                               ----                                ----                                ----                                ----

    Revenue                                                                              $919                                $842                              $2,633                              $2,492
    Cost of Products Sold                                                               460                                 405                               1,309                               1,219
                                                                                        ---                                 ---                               -----                               -----
                              Gross Margin                                              459                                 437                               1,324                               1,273

    Selling, General and Administrative Expenses                                        241                                 256                                 766                                 779
    Research and Development Expenses                                                    45                                  36                                 118                                 108
    Restructuring and Acquisition Integration Charges                                    12                                  14                                  26                                  53
    Gain on the Sale of Assets                                                            -                                 (15)                                  -                                 (15)
                                                                                        ---                                 ---                                 ---                                 ---
                              Operating Income                                          161                                 146                                 414                                 348

    Interest Expense and Other, Net                                                      21                                  18                                  63                                  59
                                                                                        ---                                 ---                                 ---                                 ---
    Income Before Income Tax                                                            140                                 128                                 351                                 289
    Provision for Income Tax                                                             37                                  42                                  85                                  91
                                                                                        ---                                 ---                                 ---                                 ---
    Income from Continuing Operations                                                   103                                  86                                 266                                 198
    Discontinued Operations:
                               Loss from the
                               Disposal of
                               Discontinued
                               Businesses,
                               Net of Tax                                               (74)                                (40)                                (74)                                (40)
                               Income (Loss)
                               from the
                               Operations of
                               Discontinued
                               Businesses,
                               Net of Tax                                                 2                                  (1)                                  1                                   1

    Loss from Discontinued Operations, Net of Tax                                       (72)                                (41)                                (73)                                (39)

    Net Income                                                                          $31                                 $45                                $193                                $159
                                                                                        ===                                 ===                                ====                                ====

    Per Share Amounts: (1)

    Basic Earnings (Loss) per Common Share:
                               Continuing
                               Operations                                             $0.46                               $0.39                               $1.19                               $0.89
                               Discontinued
                               Operations                                            $(0.32)                             $(0.18)                             $(0.33)                             $(0.18)
                               Basic Earnings
                               per Common
                               Share                                                  $0.14                               $0.20                               $0.86                               $0.71

    Diluted Earnings (Loss) per Common Share:
                               Continuing
                               Operations                                             $0.45                               $0.38                               $1.17                               $0.88
                               Discontinued
                               Operations                                            $(0.32)                             $(0.18)                             $(0.32)                             $(0.17)
                               Diluted
                               Earnings per
                               Common Share                                           $0.13                               $0.20                               $0.85                               $0.71

    Weighted-Average Number of Common Shares
     Outstanding:
                              Basic                                                   224.6                               223.0                               224.4                               222.6
                              Diluted                                                 226.8                               225.6                               226.6                               224.6

    Adjusted Financial Measures: (2)
                               Operating
                               Expenses                                                $286                                $282                                $880                                $849
                               Operating
                               Income                                                  $173                                $155                                $444                                $424
                               Income from
                               Continuing
                               Operations                                              $112                                 $94                                $288                                $256
                               Diluted EPS
                               from
                               Continuing
                               Operations                                             $0.49                               $0.42                               $1.27                               $1.14
                               Effective Tax
                               Rate                                                    26.0%                               31.6%                               24.4%                               29.8%
                               -------------                                           ----                                ----                                ----                                ----
    ____________

    (1)                        Earnings per share calculations are performed separately for
                               each component presented. Therefore, the sum of the per share
                               components from the table may not equal the per share amounts
                               presented.

    (2)                        Adjusted financial measures are non-GAAP measures that exclude
                               certain nonrecurring items, as discussed above under Use of
                               Non-GAAP Financial Measures. These measures are reconciled to
                               comparable GAAP measures in the Reconciliation of Non-GAAP
                               Financial Measures included on the pages that follow.
                                                                                                                                                CAREFUSION CORPORATION
                                                                                                                                    RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
                                                                                                                                                     (UNAUDITED)

    Adjusted Financial Data:                                                                                                                                                                                                                       Income           Diluted
                                                                                                                                    Segment Profit                                                                                  from          EPS from
                                                                                                                                    --------------
                                                                                                                                        Medical                 Procedural                   SG&A            Operating           Operating       Continuing       Continuing
    ($ in millions, except per share amounts)                                                                                           Systems                 Solutions                  Expenses         Expenses (5)           Income        Operations       Operations
                                                                                                                                        -------                 ---------                  --------         -----------            ------        ----------       ----------

    Quarter Ended March 31, 2012
    GAAP                                                                                                                                                  $125                       $36              $241                 $298            $161             $103             $0.45
                                              Restructuring and Acquisition Integration (1)                                                                  7                         5                 -                  (12)             12               12              0.05
                                              Spinoff (2)                                                                                                    -                         -                 -                    -               -                -                 -
                                              Income Tax Items (3)                                                                                           -                         -                 -                    -               -               (3)            (0.01)

    Adjusted                                                                                                                                              $132                       $41              $241                 $286            $173             $112             $0.49

    Nine Months Ended March 31, 2012
    GAAP                                                                                                                                                  $334                       $80              $766                 $910            $414             $266             $1.17
                                              Restructuring and Acquisition Integration (1)                                                                 15                        11                 -                  (26)             26               26              0.11
                                              Spinoff (2)                                                                                                    3                         1                (4)                  (4)              4                4              0.02
                                              Income Tax Items (3)                                                                                           -                         -                 -                    -               -               (8)            (0.03)

    Adjusted                                                                                                                                              $352                       $92              $762                 $880            $444             $288             $1.27

    Quarter Ended March 31, 2011
    GAAP                                                                                                                                                   $97                       $34              $256                 $306            $146              $86             $0.38
                                              Restructuring and Acquisition Integration (1)                                                                  6                         8                 -                  (14)             14               14              0.06
                                              Spinoff (2)                                                                                                    6                         4               (10)                 (10)             10               10              0.04
                                              Income Tax Items (3)                                                                                           -                         -                 -                    -               -               (1)            (0.00)
                                              Gain on the Sale of Assets (4)                                                                                 -                         -                 -                    -             (15)             (15)            (0.07)

    Adjusted                                                                                                                                              $109                       $46              $246                 $282            $155              $94             $0.42

    Nine Months Ended March 31, 2011
    GAAP                                                                                                                                                  $260                       $73              $779                 $940            $348             $198             $0.88
                                              Restructuring and Acquisition Integration (1)                                                                 29                        24                 -                  (53)             53               53              0.24
                                              Spinoff (2)                                                                                                   21                        17               (38)                 (38)             38               38              0.17
                                              Income Tax Items(3)                                                                                            -                         -                 -                    -               -              (18)            (0.08)
                                              Gain on the Sale of Assets (4)                                                                                 -                         -                 -                    -             (15)             (15)            (0.07)

    Adjusted                                                                                                                                              $310                      $114              $741                 $849            $424             $256             $1.14

    Fiscal Year 2011
    GAAP                                                                                                                                                  $375                      $109            $1,067               $1,277            $497             $294             $1.30
                                              Restructuring and Acquisition Integration (1)                                                                 34                        30                 -                  (64)             64               64              0.29
                                              Spinoff (2)                                                                                                   31                        24               (55)                 (55)             55               55              0.25
                                              Income Tax Items (3)                                                                                           -                         -                 -                    -               -              (26)            (0.12)
                                              Gain on the Sale of Assets (4)                                                                                 -                         -                 -                    -             (13)             (13)            (0.06)

    Adjusted                                                                                                                                              $440                      $163            $1,012               $1,158            $603             $374             $1.66

    ____________

    (1)                                        Restructuring and acquisition integration charges primarily relate to nonrecurring expenses associated with closing and consolidating facilities,
                                               as well as rationalizing headcount, and aligning operations.

    (2)                                       Spinoff charges primarily relate to nonrecurring incremental expenses associated with our spinoff from Cardinal Health, Inc.

    (3)                                        Income tax items primarily relate to the tax impact of nonrecurring restructuring and acquisition integration and spinoff charges, as well as
                                               nonrecurring discrete benefits or charges associated with the spinoff.

    (4)                                        The $15 million gain on the sale of assets associated with the March 2011 divestiture of our OnSite Services business has not been allocated to
                                               segment results for the quarter and nine months ended March 31, 2011.

    (5)                                        Operating expenses consist of selling, general and administrative, research and development, and restructuring and acquisition integration
                                               expenses.
                                                                                         CAREFUSION CORPORATION
                                                                             RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
                                                                                              (UNAUDITED)

    Adjusted Effective Tax Rate:
                                                                                                                                                          Nonrecurring
    ($ in millions)                                                                                                             GAAP           Items (1)               Adjusted (2)
    --------------                                                                                                              ----           --------                 -----------
    Quarter Ended March 31, 2012
                                                                          Income Before Income Tax                                                  $140                         $12  $152
                                                                          Provision for Income Tax                                                   $37                          $3   $40
                                                                          Effective Tax Rate (3)                                                    26.1%                       23.0% 26.0%

    Nine Months Ended March 31, 2012
                                                                          Income Before Income Tax                                                  $351                         $30  $381
                                                                          Provision for Income Tax                                                   $85                          $8   $93
                                                                          Effective Tax Rate (3)                                                    24.2%                       26.7% 24.4%

    Quarter Ended March 31, 2011
                                                                          Income Before Income Tax                                                  $128                          $9  $137
                                                                          Provision for Income Tax                                                   $42                          $1   $43
                                                                          Effective Tax Rate (3)                                                    32.6%                       17.9% 31.6%

    Nine Months Ended March 31, 2011
                                                                          Income Before Income Tax                                                  $289                         $76  $365
                                                                          Provision for Income Tax                                                   $91                         $18  $109
                                                                          Effective Tax Rate (3)                                                    31.4%                       23.8% 29.8%

    Fiscal Year Ended June 30, 2011
                                                                          Income Before Income Tax                                                  $418                        $106  $524
                                                                          Provision for Income Tax                                                  $124                         $26  $150
                                                                          Effective Tax Rate (3)                                                    29.8%                       24.3% 28.7%

    Adjusted EPS Outlook for Fiscal Year Ended June 30, 2012:

    GAAP Diluted Earnings per Common Share from Continuing Operations                                                    $   1.65 - 1.70

                                                                           Estimated charges for nonrecurring items related to
                                                                           restructuring and acquisition integration
                                                                           (mid-point of an estimated range
                                                                           of $0.10 to $0.14 per diluted
                                                                           share)                                                                                              0.12

                                                                           Estimated charges for nonrecurring
                                                                           items related to the spinoff
                                                                           (mid-point of an estimated range
                                                                           of $0.01 to $0.03 per diluted
                                                                           share)                                                                                              0.02

                                                                           Estimated charges
                                                                           related to
                                                                           nonrecurring income
                                                                           tax items
                                                                           (mid-point of an estimated range
                                                                            of $0.03 to $0.05 per diluted
                                                                            share)                                                                                            (0.04)

    Adjusted Diluted Earnings per Common Share from Continuing Operations                                                $   1.75 - 1.80

    ____________

    (1)                                                                    Reflects nonrecurring charges primarily related to the spinoff,
                                                                           nonrecurring restructuring and acquisition integration charges, and
                                                                           nonrecurring income tax items.

    (2)                                                                    Adjusted financial information reflects GAAP results adjusted on a
                                                                           non-GAAP basis to exclude nonrecurring items noted.

    (3)                                                                    Effective tax rate calculations are performed based on whole dollar
                                                                           amounts, and therefore may not equal the calculations based on
                                                                           amounts rounded in millions presented in the table above.

                                                                                                                            CAREFUSION CORPORATION
                                                                                                                  SEGMENT AND SELECT BUSINESS LINE REVENUES
                                                                                                                                 (UNAUDITED)

                                                                     Quarter Ended                                                                          Nine Months Ended
                                                                       March 31,                                                                                March 31,
                                                                       ---------                                                                                ---------
    ($ in millions)                                                               2012                           2011          Percent                                                         2012                             2011          Percent
                                                                                                                                Change                                                                                                         Change
    ---                                                                                                                         ------                                                                                                         ------
    Medical Systems
                           Dispensing
                           Technologies                                         $261                           $210                       24%                                                $756                             $644                       17%
                           Infusion
                           Systems                                              $245                           $213                       15%                                                $690                             $628                       10%
                           Respiratory
                           Technologies                                          $78                            $69                       13%                                                $207                             $199                        4%
                          Other                                                   $7                             $6                       17%                                                 $19                              $18                        6%

                          Total Medical Systems                                 $591                           $498                       19%                                              $1,672                           $1,489                       12%

    Procedural Solutions (1)
                           Infection
                           Prevention                                           $150                           $144                        4%                                                $430                             $421                        2%
                           Medical
                           Specialties                                           $80                            $82                      (2)%                                                $237                             $238                      (0)%
                           Specialty
                           Disposables                                           $70                            $78                     (10)%                                                $201                             $221                      (9)%
                          Other                                                  $28                            $40                     (30)%                                                 $93                             $123                     (24)%

                          Total Procedural Solutions                            $328                           $344                      (5)%                                                $961                           $1,003                      (4)%

                           Total
                           CareFusion                                           $919                           $842                        9%                                              $2,633                           $2,492                        6%

    ____________

                     (1)  Reflects the impact of businesses reclassified to discontinued operations.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

SOURCE CareFusion Corp.


Source: PR Newswire